Cargando…
No Time to Lose: Cases of Anticoagulant Reversal Before Thrombolysis in Acute Ischemic Stroke Patients
Direct oral anticoagulant (DOAC) reversal before intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients is well-documented in Europe, specifically for dabigatran: the selective humanized monoclonal antibody fragment idarucizumab, given to neutralize dabigatran prior to IVT, was assoc...
Autores principales: | Amin, Sheyar, Kasischke, Karl A, Elsayed, Kareem, Burgin, W. Scott, Rose, David Z |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8856630/ https://www.ncbi.nlm.nih.gov/pubmed/35198313 http://dx.doi.org/10.7759/cureus.21406 |
Ejemplares similares
-
Intravenous Thrombolysis in Ischemic Stroke Patients With Active Cancer
por: Selvik, Henriette Aurora, et al.
Publicado: (2018) -
Pre-treatment of Single and Double Antiplatelet and Anticoagulant With Intravenous Thrombolysis for Older Adults With Acute Ischemic Stroke: The TTT-AIS Experience
por: Lin, Sheng-Feng, et al.
Publicado: (2021) -
Characteristics and Outcomes of Intravenous Thrombolysis in Mild Ischemic Stroke Patients
por: Tang, Huan, et al.
Publicado: (2021) -
Corrigendum: Pre-treatment of Single and Double Antiplatelet and Anticoagulant With Intravenous Thrombolysis for Older Adults With Acute Ischemic Stroke: The TTT-AIS Experience
por: Lin, Sheng-Feng, et al.
Publicado: (2021) -
Predictive Factors of Hemorrhage After Thrombolysis in Patients With Acute Ischemic Stroke
por: Sun, Fan, et al.
Publicado: (2020)